Connection between M. tuberculosis and M. bovis
M. tuberculosis and M. bovis are closely related members of the M. tuberculosis complex (>99.95% genomic identity) that both cause tuberculosis, but differ in primary hosts, transmission routes, and drug susceptibility, with important implications for morbidity, mortality, and quality of life 1.
Taxonomy and genetics
- Both are MTBC species; genomes are >99.95% identical, with M. bovis having specific deletions/SNPs and differential gene expression that drive host tropism and phenotype 1, 2.
- No genes uniquely present in M. bovis vs M. tuberculosis; differences reflect deletions and regulation (e.g., RD regions, regulatory protein polymorphisms) 1, 2.
Hosts and transmission
- M. tuberculosis: human-adapted; spread mainly by airborne person-to-person transmission, the key driver of human TB burden 3.
- M. bovis: bovine-adapted; transmits to humans primarily via unpasteurized dairy/animal exposure; aerosol transmission can occur but is less clearly defined; animal-to-human transmission confirmed in necropsy settings 3.
- Public health: pasteurization prevents most foodborne M. bovis; exposure events in labs/animal procedures require airborne precautions due to aerosol generation risk 3.
Clinical implications for patients (impacting morbidity, mortality, QOL)
- Disease patterns: Ingested M. bovis more often causes extrapulmonary TB (e.g., scrofula, peritonitis), though pulmonary disease is possible; manage contact investigations as for pulmonary TB, noting uncertain transmissibility 3.
- Diagnosis:
- TST and IGRAs detect infection by MTBC, including M. bovis; IGRAs use antigens (ESAT-6/CFP-10) absent from BCG strains but present in wild-type M. bovis and M. tuberculosis, improving specificity in BCG-vaccinated persons 4.
- BCG vaccine (attenuated M. bovis) causes false-positive TST but not IGRA reactivity, which matters for screening accuracy and downstream outcomes 5, 4.
- Treatment:
- Treat latent or active M. bovis infection as TB caused by M. tuberculosis, with the critical caveat that M. bovis is intrinsically resistant to pyrazinamide—adjust regimens accordingly to prevent failure/relapse and excess mortality (guidelines emphasize treating suspected latent M. bovis as ordinary TB after ruling out active disease) 3.
- Vaccination:
- BCG is derived from attenuated M. bovis; not used routinely in the US, but globally reduces severe pediatric TB (meningitis/miliary), improving survival and long-term QOL; its origin explains TST cross-reactions 6.
Practical, guideline-framed takeaways
- Source and route matter:
- Testing strategy to optimize outcomes:
- Prefer IGRA over TST in BCG-vaccinated individuals to avoid false positives that can lead to unnecessary treatment and QOL impact; both detect MTBC including M. bovis (BCG strains do not express IGRA antigens) 4.
- Treatment nuance that changes prognosis:
- If M. bovis suspected/confirmed, avoid pyrazinamide and extend/adjust regimen to prevent treatment failure and reduce morbidity/mortality; otherwise manage per TB standards 3.
Common pitfalls (and how to avoid them)
- Misattributing TST positivity to infection in BCG-vaccinated patients—use IGRA to improve specificity 4.
- Using pyrazinamide in M. bovis disease—verify species when epidemiology suggests bovine exposure; adjust regimen to avoid poor outcomes 3.
- Under-recognizing extrapulmonary TB after dairy exposure—actively consider lymphadenitis/peritoneal TB to prevent delays that worsen morbidity 3.